Russian biotech company GEROPHARM has announced a new stage in its program to increase the accessibility of obesity therapy. Starting February 10, 2026, the cost of the drugs “Semavik” (analogous to Ozempic) and “Sejaro” (analogous to Mounjaro) in the country’s pharmacy chains has been reduced by up to 19%.
This move is aimed at supporting patients seeking weight loss and makes modern treatment methods even more accessible to a wide audience. The company is paying special attention to “Sejaro”. Even at the start of sales in Russia, its cost was 60% lower than existing analogs. The current price reduction solidifies “Sejaro’s” status as the most affordable tirzepatide not only in Russia but in the world.
“It is fundamentally important for us that modern obesity treatment methods are available to as many patients as possible. Our goal is not just to offer a medicine, but to give people tools for long-term lifestyle changes. And every step toward reducing costs is an opportunity for patients to start this journey.”
— Petr Rodionov, CEO of GEROPHARM
Estimated Prices in Russia (after reduction from February 10, 2026)
- Sejaro (tirzepatide), 2.5 mg: ~4,700 – 5,500 RUB (previously 5,500 – 6,737 RUB). Mounjaro analog, the most affordable tirzepatide on the market.
- Semavik (semaglutide), 0.25–1 mg: ~3,500 – 4,200 RUB (previously 4,279 – 5,233 RUB). Ozempic analog, with a price significantly lower than the reference drug.
Global Context: Comparing Accessibility in Russia and the USA
To assess the scale of prices on the global market, one should look at the situation in the USA. In February 2026, the state platform TrumpRx began operations there, providing uninsured citizens with discounts of up to 81% on original drugs. However, even with such significant discounts in the American market, Russian analogs remains substantially cheaper.
Below is a price comparison in US dollars (calculated at an exchange rate of 80 RUB / $1):
| Drug (Russia / USA) | Price in Russia (USD) | Price in USA (TrumpRx, USD) | Standard Price in USA (USD) | Difference (Russia / USA) |
|---|---|---|---|---|
| Semavik / Ozempic | $44 – $53 | from $199 | $1,027 | 4–5 times cheaper |
| Sejaro / Zepbound (Mounjaro) | $59 – $69 | from $299 | $1,087 | 5 times cheaper |
Calculations show that despite large-scale state initiatives in the USA to reduce drug costs through the TrumpRx system, original drugs for American patients remain 4–5 times more expensive than Russian biotechnological solutions from GEROPHARM.
